![]() |
市場調査レポート
商品コード
1494815
医療用メンブレン市場の2030年までの予測:材料別、技術別、用途別、エンドユーザー別、地域別の世界分析Medical Membranes Market Forecasts to 2030 - Global Analysis By Material, Technology, Application, End User and By Geography |
||||||
カスタマイズ可能
|
医療用メンブレン市場の2030年までの予測:材料別、技術別、用途別、エンドユーザー別、地域別の世界分析 |
出版日: 2024年06月06日
発行: Stratistics Market Research Consulting
ページ情報: 英文 200+ Pages
納期: 2~3営業日
|
Stratistics MRCによると、医療用メンブレンの世界市場は2024年に40億米ドルを占め、予測期間中のCAGRは11.2%で成長し、2030年には77億米ドルに達すると予測されています。
医療用メンブレンは様々な医療用途、特にヘルスケア環境と生物医学研究に使用される特殊材料です。これらの膜は薄い半透膜構造で、特定の物質の通過を選択的に許し、他の物質の通過を遮断します。医療機器や処置におけるろ過、分離、ドラッグデリバリーなど、特定の機能を果たすように設計されています。医療用メンブレンは、腎不全治療のための血液透析、心肺バイパス装置における血液酸素供給、医薬品や生物学的液体のろ過、経皮パッチやインプラントにおける薬剤の放出制御など、幅広い用途で利用されています。
慢性疾患の増加
末期腎不全(ESRD)などの慢性疾患は腎不全につながるため、血液透析や腹膜透析などの腎代替療法が必要になります。膜ベースの透析システムは、血液から老廃物や余分な水分をろ過する特殊な膜に依存しています。腎臓病の危険因子である高血圧や糖尿病などの病態の蔓延が、透析膜の需要を押し上げ、ひいては市場の成長を牽引しています。
高度な透析膜の高コスト
ヘルスケアプロバイダーや保険会社は、高度な膜ベースの医療技術のコストをカバーする上で課題に直面する可能性があり、患者の自己負担額や医療保険料の増加につながります。これは家計を圧迫し、特に継続的な治療を必要とする慢性疾患や複雑な病状の患者にとっては、医療を受ける余裕に影響を与える可能性があり、市場成長の妨げとなります。
高純度製品に対する需要の高まり
高純度製品に対する需要の高まりは、膜技術の革新と進歩を促し、選択性、効率、信頼性を向上させた膜の開発につながります。メーカーは、医療や製薬産業における高純度アプリケーションの特定の要件を満たすために、特性を調整した膜を設計する研究開発努力に投資し、市場の成長を推進しています。
長い工程内バリデーション
広範なバリデーション要件は、新しい膜製品の市場投入に関連する開発コストを増加させる。メーカーは、バリデーション研究の実施、規制当局の承認取得、品質基準や規制への準拠を確保するためにリソースを割かなければならず、開発費の増加につながり、利益率を低下させたり、市場参入や拡大努力を妨げる研究開発への投資を抑止したりする可能性があります。
COVID-19の影響
世界はCOVID-19のパンデミックと戦っており、COVID-19は世界中に広がっています。医療用メンブレンは主に医薬品ろ過、輸液・無菌ろ過、バイオ人工プロセス、ドラッグデリバリー、血液透析に使用されており、国家封鎖の影響として、これらの分野は成長率が若干低下しています。多くの国では、いくつかの産業、特に輸送とサプライチェーンの停止により経済が落ち込んでいます。ロックダウンのため開発が進まず、需要が妨げられています。需給ギャップ、原料調達の混乱、価格変動は、COVID-19パンデミックの間、化学産業の成長を妨げると予想されます。
ポリプロピレン(PP)セグメントが予測期間中最大になる見込み
ポリプロピレン(PP)は生体適合性で知られ、生体組織や体液と接触しても免疫反応や副作用を引き起こしにくいことから、予測期間中に最大となる見込みです。この特性により、PPはろ過、ドラッグデリバリー、組織工学などの用途に使用される医療用メンブレンにとって魅力的な材料となっています。さらに、PPは優れた機械的特性を持ち、医療業界で一般的に使用される様々な滅菌方法に適合する能力があるため、市場の成長を後押ししています。
ナノろ過分野は予測期間中に最も高いCAGRが見込まれる
ナノろ過膜は限外ろ過膜に比べて孔径が小さいため、大きな分子は通過させながら小さな分子を選択的に除去することができます。この選択的ろ過能力は、透析、医薬品精製、血漿分画など、分子や粒子の正確な分離が求められる医療用途に有利です。
北米は、人々の意識の高まり、より良い医療施設の利用可能性、革新的な製品の高い採用率、人口の慢性腎臓病の有病率の増加により、予測期間中最大の市場シェアを占めると予測されています。例えば、国立糖尿病・消化器・腎臓病研究所(National Institute of Diabetes and Digestive and Kidney Disease)の2016年報告書によると、661,000人以上の米国人が腎不全の問題に苦しんでおり、このうち468,000人が透析を受けています。
アジア太平洋地域は、様々な慢性疾患や感染症に罹患しやすい人口が多いことから、予測期間中に最も高いCAGRを維持すると予測されています。そのため、革新的な技術のイントロダクションより、患者に低コストでより良いソリューションを提供することが期待されています。医療用メンブレン市場は、エンドユーザーからの需要増加に対応するための製造施設の増加により、アジア太平洋地域で大きな成長率を示しています。例えば、メドトロニック社は2014年に中国に新しい製造施設を開設し、血液透析システム製品の製造の大半をここで行う予定です。
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.
According to Stratistics MRC, the Global Medical Membranes Market is accounted for $4.0 billion in 2024 and is expected to reach $7.7 billion by 2030 growing at a CAGR of 11.2% during the forecast period. Medical membranes are specialized materials used in various medical applications, particularly in healthcare settings and biomedical research. These membranes are thin, semi-permeable structures that selectively allow the passage of certain substances while blocking others. They are designed to perform specific functions such as filtration, separation, or drug delivery in medical devices and procedures. Medical membranes are utilized in a wide range of applications, including hemodialysis for kidney failure treatment, blood oxygenation in cardiopulmonary bypass machines, filtration of pharmaceuticals and biological fluids, and controlled release of drugs in transdermal patches or implants.
Rising prevalence of chronic diseases
Chronic diseases such as end-stage renal disease (ESRD) lead to kidney failure, necessitating renal replacement therapies like hemodialysis or peritoneal dialysis. Membrane-based dialysis systems rely on specialized membranes to filter waste products and excess fluids from the blood. The growing prevalence of conditions like hypertension and diabetes, which are risk factors for kidney disease, drives the demand for dialysis membranes which in turn drive the growth of the market.
High cost of advanced membranes
Healthcare providers and insurers may face challenges in covering the costs of advanced membrane-based medical technologies, leading to higher out-of-pocket expenses for patients or increased healthcare premiums. This can strain household budgets and impact the affordability of medical care, especially for individuals with chronic or complex medical conditions requiring ongoing treatment thus hampering the market growth.
Growing demand for high-purity products
The growing demand for high-purity products drives innovation and advancement in membrane technology, leading to the development of membranes with improved selectivity, efficiency, and reliability. Manufacturers invest in research and development efforts to engineer membranes with tailored properties to meet the specific requirements of high-purity applications in the medical and pharmaceutical industries propel the market growth.
Long in-process validation
Extensive validation requirements add to the development costs associated with bringing new membrane products to market. Manufacturers must allocate resources for conducting validation studies, acquiring regulatory approvals, and ensuring compliance with quality standards and regulations, leading to increased development expenses that may reduce profit margins or deter investment in research and development impeding market entry or expansion efforts.
Covid-19 Impact
The world is battling the contagious COVID-19 pandemic, which has spread across the globe. Medical membrane is primarily used in pharmaceutical filtration, IV Infusion & sterile filtration, bio-artificial processes, drug delivery, and hemodialysis; and as an impact of national lockdown, these sectors were experiencing a slight decline in growth rates. In many countries, the economy has dropped due to the halt of several industries, especially transport and supply chain. Demand for the product has been hindered as there is no development due to the lockdown. The demand-supply gap, disruptions in raw material procurement, and price volatility are expected to hamper the growth of the chemical industry during the COVID-19 pandemic.
The polypropylene (PP) segment is expected to be the largest during the forecast period
The polypropylene (PP) is expected to be the largest during the forecast period as it is known for its biocompatibility, meaning it is unlikely to cause an immune response or adverse reactions when in contact with biological tissues or fluids. This property makes PP an attractive material for medical membranes used in applications such as filtration, drug delivery, and tissue engineering. Moreover it has excellent mechanical properties and ability to compatible with various sterilization methods commonly used in the medical industry drive the growth of the market
The nanofiltration segment is expected to have the highest CAGR during the forecast period
The nanofiltration segment is expected to have the highest CAGR during the forecast period as nanofiltration membranes have smaller pore sizes compared to ultrafiltration membranes, allowing them to selectively remove smaller molecules while allowing the passage of larger ones. This selective filtration capability is advantageous in medical applications where precise separation of molecules or particles is required, such as in dialysis, pharmaceutical purification, and blood plasma fractionation.
North America is projected to hold the largest market share during the forecast period owing to increasing awareness among the people, availability of better medical facilities, high adoption of the innovative products and increasing prevalence of chronic kidney disorder among the population. For instance, according to the National Institute of Diabetes and Digestive and Kidney Disease 2016 report, more than 661,000 Americans were suffering from kidney failure problems and out of these 468,000 individuals were on dialysis.
Asia Pacific is projected to hold the highest CAGR over the forecast period owing to presence of large population prone to various chronic and infectious diseases. Therefore, introduction of innovative techniques are expected to provide better solutions to the patient at the low costs. Medical membrane market is growing at significant rate in the Asia Pacific region, owing to increasing manufacturing facilities to meet increasing demand from end users. For instance, Medtronic opened its new manufacturing facility in China in 2014, in which the company will be focusing most of its hemodialysis system products manufacturing.
Key players in the market
Some of the key players in Medical Membranes market include 3M Company, Abbott, Aethlon Medical, Inc., Agilent Technologies, Inc., Amniox Medical, Asahi Kasei, Danaher Corporation, F. Hoffmann-La Roche Ltd, Hangzhou Cobetter Filtration Equipment, Johnson & Johnson Services, Inc, Koch Membrane Systems, Mann+Hummel, Medtronic, Merck Group, NIPRO, Pall Corporation, Sartorius AG, Siemens, Thermo Fisher Scientific Inc. and W. L. Gore & Associates
In May 2024, 3M expands facility in Valley, Nebraska. The expansion of the plant is expected to create about 40 new jobs. The $67 million investment includes new production lines, equipment and a warehouse, and will help 3M more quickly meet customer demand for the company's personal safety products.
In March 2024, Abbott, Real Madrid and the Real Madrid Foundation announced the extension of their partnership through Real Madrid's 2026-27 season. Abbott will remain Global Health Sciences and Nutrition Partner of Real Madrid Football Club and Global Partner of the Real Madrid Foundation.
In February 2024, Aethlon Medical Enters Into Materials Transfer Agreement for Santersus AG's NucleoCapture and HemoNucleoCapture Devices. Aethlon Medical Will Perform Pre-Clinical Studies to Explore Potential Synergies With its First-in-Class Hemopurifier(R) Blood Filtration System